Reply: Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies

Journal of the American College of Cardiology

Volumn 62, Issue 25, 2013, Pages 2452-

  Bosch, Xavier ^a   Sitges, Marta ^a   Rovira, Montserrat ^a   Ortiz Pérez, José Tomás ^a   Esteve, Jordi ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTHRACYCLINE; CARVEDILOL; ENALAPRIL; TROPONIN;

ACUTE LEUKEMIA; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR MORTALITY; CHEMOTHERAPY INDUCED LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; HEART FAILURE; HEART PROTECTION; HEMATOLOGIC MALIGNANCY; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LETTER; PRIORITY JOURNAL; SEPSIS;

EID: 84890672619     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.08.712     Document Type: Letter

References (3)

1. X. Bosch, M. Rovira, and M. Sitges Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies) J Am Coll Cardiol 61 2013 2355 2362
2. P.G. Morris, C. Chen, and R. Steingart Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib Clin Cancer Res 17 2011 3490 3499
3. D. Cardinale, A. Colombo, and M.T. Sandri Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin converting enzyme inhibition Circulation 114 2006 2474 2481